CSI Market
Sign In | Register

Bridgebio Pharma Inc (BBIO) Annual Cash Flow Statement

Annual · GAAP · USD millions
Access BBIO quarterly Cash Flow →
The quarterly cash flow data below helps track how Bridgebio Pharma Inc's liquidity profile has evolved over recent quarters.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Annual Report, GAAP in USD millions
ITEM 		(Dec 31 2025)
12 Months 		(Dec 31 2024) (Dec 31 2023) (Dec 31 2022) (Dec 31 2021)
Operating Activities
Income-732.94
Depreciation & amortization5.43
Amortization of Other Assets5.97
Increase (Decrease) in Deferred Revenue-11.43
Impairment of Long-Lived Assets Held-for-use0.00
Provision For Loan Losses Expensed0.00
Increase (Decrease) in Inventories-25.31
Research and Development in Process0.00
Gain (Loss) on Disposition of Assets, Total0.00
Share-based Compensation133.02
Income (Loss) from Equity Method Investments72.61
Gains (Losses) on Extinguishment of Debt21.16
Shares Issued Under License Agreement-
Call Option Expense-
Change In Fair Value Of Financial Instruments-
Increase Decrease In Accrued Compensation And Benefits-
Increase Decrease In Accrued Research And Development Liabilities7.16
Transfers To From Non Controlling Interest-
Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction-
Conversion Of Redeemable Noncontrolling Interest Into Noncontrolling Interest-
Deconsolidation Gain Or Loss Amount-
Fair Value Of Equity Method Investment-
Operating Lease Right Of Use Asset Amortization Expense4.90
Noncash Lease Expense-
Equity Securities Fv Ni Gain Loss-
Gain From Sale Of Priority Review Voucher Excluding Transaction Costs-
Noncash Interest Expense On Deferred Royalty Obligations125.14
Increase Decrease Receivable From Licensing And Collaboration Agreements-
Income taxes0.00
Loss on Sale of Investments0.00
Accounts Receivable-111.70
Increase (Decrease) in Accounts Payable26.61
Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities0.00
Deferred Revenue and Customer Advances and Deposits0.00
Increase (Decrease) in Prepaid Expense and Other Assets-8.78
Other Working Capital78.92
Other Noncash Income (Expense)-1.65
Other net0.00
Payments for (Proceeds from) Other Operating Activities-35.03
Discontinued operations0.00
Net Cash flow from Operating Activities-445.91
Investing Activities
Capital Expenditures-9.59
Sale of Capital Items0.00
Proceeds from Sale and Maturity of Available-for-sale Securities11.00
Payments to Acquire Available-for-sale Securities, Debt-28.20
Payments for Tenant Improvements0.00
Payments Of Merger Related Costs Investing Activities-
Cash And Cash Equivalents Acquired Not Part Of Business Acquisition-
Proceeds From Consolidation Of Entities-
Proceeds From Sale Of Marketable Securities-
Payments To Acquire Equity Securities Fv Ni-
Decrease In Cash And Cash Equivalents Resulting From Deconsolidation Of Entities-
Restricted Cash and Investments Increase (Decrease)0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments for (Proceeds from) Other Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Acquisition Net of Cash Acquired0.00
Proceeds from Equity Method Investment, Dividends or Distributions, Return of Capital2.30
Sale of businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities-24.49
Financing Activities
Short-term debt Net-459.00
Other borrowing transactions0.00
Long-term debt - borrowings575.00
Long-term debt - repayments0.00
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock-14.13
Payments of Distributions to Affiliates0.00
Issuances / -repurchases of Pref. Stock2.15
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net255.27
Proceeds From Issuance Of Promissory Notes-
Proceeds From Subsidiary Stock Options Exercises-
Proceeds From Third Party Investors In Redeemable Convertible Noncontrolling Interests-
Purchase Of Capped Calls-
Proceeds From Issuance Of Redeemable Convertible Noncontrolling Interests To Third Party Investors-
Stock Issued No Premium-
Payment Of Deferred Offering Costs-
Proceeds From Issuance Of Noncontrolling Interest-
Proceeds From Issuance Of Noncontrolling Interests-
Repurchase Of Noncontrolling Interest Including Direct Transaction Costs-
Proceeds From Issuance Of Common Stock Through At The Market Offering Net-
Financing Activity Transactions With Noncontrolling Interests-
Proceeds From Royalty Obligation Under Funding Agreement-
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities359.29
Effect of exchange rate on cash flow0.00
Discontinued operations0.00
Free Cash Flow-455.50
Total Cash Flow-111.10
4 historic quarters locked

Sign in to unlock the full Bridgebio Pharma Inc cash flow history.

Sign In Create Free Account

About Bridgebio Pharma Inc Annual Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-K filings and normalized by CSIMarket.

Source & verification

  • Form: 10-K (Period: 20251231)
  • Filed with the SEC: February 24, 2026
  • Source: bbio-20251231.htm

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0001743881-26-000009

Figures are derived from filed reports and may be restated. Historical data is subject to revision.

Untitled Document 





                    


    



  Get the full CSIMarket dataset:
  Subscribe
  API
  License